These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 23535815

  • 1. Acute pulmonary emboli in a patient on long-term dabigatran therapy.
    Rafferty JA, Prom R, Kujawski SZ.
    Ann Pharmacother; 2013 Apr; 47(4):e20. PubMed ID: 23535815
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.
    Ann Intern Med; 2011 Jan 04; 154(1):1-11. PubMed ID: 21041570
    [Abstract] [Full Text] [Related]

  • 3. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.
    Wychowski MK, Kouides PA.
    Ann Pharmacother; 2012 Apr 04; 46(4):e10. PubMed ID: 22496474
    [Abstract] [Full Text] [Related]

  • 4. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.
    Circulation; 2011 May 31; 123(21):2363-72. PubMed ID: 21576658
    [Abstract] [Full Text] [Related]

  • 5. Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
    Alonso-Coello P, Zhou Q, Guyatt G.
    Thromb Haemost; 2012 Oct 31; 108(4):647-53. PubMed ID: 22918481
    [Abstract] [Full Text] [Related]

  • 6. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 31; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 7. Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
    Baruch L, Sherman O.
    Ann Pharmacother; 2011 Jul 31; 45(7-8):e40. PubMed ID: 21712509
    [Abstract] [Full Text] [Related]

  • 8. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
    Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.
    J Stroke Cerebrovasc Dis; 2012 Apr 31; 21(3):165-73. PubMed ID: 22440950
    [Abstract] [Full Text] [Related]

  • 9. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ.
    Circulation; 2012 Feb 07; 125(5):669-76. PubMed ID: 22215856
    [Abstract] [Full Text] [Related]

  • 10. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M, RE-LY Investigators.
    Circulation; 2012 Jul 17; 126(3):343-8. PubMed ID: 22700854
    [Abstract] [Full Text] [Related]

  • 11. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
    Fieland D, Taylor M.
    Ann Pharmacother; 2012 Jan 17; 46(1):e3. PubMed ID: 22202498
    [Abstract] [Full Text] [Related]

  • 12. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb 17; 21(124):33-6. PubMed ID: 22413715
    [Abstract] [Full Text] [Related]

  • 13. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S.
    Circulation; 2013 Jul 16; 128(3):237-43. PubMed ID: 23770747
    [Abstract] [Full Text] [Related]

  • 14. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A, Bailey C, Abdelhafiz AH.
    Age Ageing; 2012 Sep 16; 41(5):681-4. PubMed ID: 22378612
    [Abstract] [Full Text] [Related]

  • 15. Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation.
    Huang C, Siu M, Vu L, Wong S, Shin J.
    J Eval Clin Pract; 2013 Oct 16; 19(5):938-43. PubMed ID: 22834964
    [Abstract] [Full Text] [Related]

  • 16. Hemopericardium in a patient treated with dabigatran etexilate.
    Barton CA, McMillian WD, Raza SS, Keller RE.
    Pharmacotherapy; 2012 May 16; 32(5):e103-7. PubMed ID: 22488474
    [Abstract] [Full Text] [Related]

  • 17. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY.
    Thromb Haemost; 2013 Feb 16; 109(2):328-36. PubMed ID: 23179181
    [Abstract] [Full Text] [Related]

  • 18. Dabigatran in patients with nonvalvular atrial fibrillation.
    Gage L.
    J Am Coll Cardiol; 2011 Jul 26; 58(5):551; author reply 551. PubMed ID: 21777759
    [No Abstract] [Full Text] [Related]

  • 19. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
    Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C, Italian Federation of Thrombosis Centers.
    Thromb Haemost; 2011 Nov 26; 106(5):868-76. PubMed ID: 21946939
    [Abstract] [Full Text] [Related]

  • 20. Dabigatran "non-inferior" to warfarin, but only just.
    BMJ; 2013 Feb 27; 346():f1219. PubMed ID: 23447339
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.